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Botulinum toxin has been used for the treatment of many clinical disorders by producing temporary skeletal 
muscle relaxation. In pain management, botulinum toxin has demonstrated an analgesic effect by reducing 
muscular hyperactivity, but recent studies suggest this neurotoxin could have direct analgesic mechanisms 
different from its neuromuscular actions. At the moment, botulinum toxin is widely investigated and used in 
many painful diseases such as myofascial syndrome, headaches, arthritis, and neuropathic pain. Further studies 
are needed to understand the exact analgesic mechanisms, efficacy and complications of botulinum toxin in 
chronic pain disorders. (Korean  J  Pain  2011;  24:  1-6)
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    Botulinum toxin (BTX) is a pre-synaptic neuromuscular 
blocking agent that triggers chemical denervation by tem-
p o r a r i l y  s u p p r e s s i n g  s e c r e t i o n  o f  a c e t y l c h o l i n e  a t  m o t o r 
nerve  endings;  therefore,  BTX  injections  are  useful  for 
diseases  with  increased  involuntary  muscle  activity  or 
tension [1]. 
    J ustinus Kerner first reported on a case of death from 
BTX found in smoked sausage (botulus in Latin) in 1817, 
but the possibility f or medica l use w as suggested m u ch 
later [2]. After Alan Scott first used BTX-A for the treat-
m e n t  o f  s t r a b i s m u s ,  B T X  i n j e c t i o n s  h a v e  b e e n  u s e d  i n 
many diseases, and its uses are continually expanding [2]. 
This review will focus mainly on the use of BTX in pain 
disorders. 
MODE  OF  ACTION
    BTX, a strong bacterial toxin, is created from f ermen-
tation of clostridium botulinum. BTX is a 300-900 kilo-
dalton (kDa) protein complex, and the structure and total 
molecular weight is different depending on the type of bac-
teria and serotype. This protein complex is stable in acid 
but is decomposed in a physiological state to yield 150 kDa 
of neurotoxin composed of two chains. Eight different se-
rotypes (A, B, C1, C2, D, E, F, G) are known, and 7 of 
these (not C2) are neurotoxins [3]. All types suppress se-
cretion of acetylcholine at nerve endings, but there are 
d i f f e r e n c e s  i n  i n t r a c e l l u l a r  p r o t e i n ,  m o d e  o f  a c t i o n ,  a n d 
effectiveness. From these, type A has been the most re-2 Korean J Pain Vol. 24, No. 1, 2011
searched, and studies about the effects of other serotypes 
are on the increase. BTX is a neurotoxin that irreversibly 
combines with the pre-synaptic membrane of motor nerve 
endings, and this unique combination selectively acts on 
cholinergic  synapses  to  suppress  the  secretion  of  ace-
tylcholine. However, it does not affect nerve conduction or 
the production and storage of acetylcholine. Neurotoxins 
e n t e r  m u s c l e  n e r v e  e n d i n g s  t h r o u g h  p r e - s y n a p t i c  r e -
ceptors via endocytosis and then are separated into two 
polypeptide chains by a protease. The separation rate of 
the chains is different depending on serotype: BTX-A sep-
arates 90-95%, whereas BTX-B separates only about 70% 
[3]. Heavy chains (100 kDa) internalize the toxin in the cell, 
while light chains (50 kDa) move to the cytosol through 
the  vesicular  membrane  and  specifically  sever  SNARE 
(Soluble NSF Attachment Protein Receptors) proteins in-
volved with exocytosis of synaptic vesicles. The destruction 
of SNARE composites interferes with attachment of syn-
aptic vesicles on the cell membrane, which cuts off the 
convergence of vesicles, and finally leads to suppression 
of acetylcholine secretion and induction of chemical de-
nervation to paralyze muscle fiber [3]. The final effect of 
all  serotype  toxins  appears  to  be  suppression  of  ace-
tylcholine secretion; however, each serotype destroys dif-
ferent areas of the SNARE protein, so action and potency 
are diverse [2]. 
    The clinical effects of BTX appear to be weakness or 
paralysis of capacity proportional skeletal muscles. When 
a appropriate amount of BTX is injected into the muscle, 
partial chemical denervation is induced to reduce muscle 
contraction  without  complete  paralysis  and  secretion  of 
glandular tissues. The initial action of BTX on the muscle 
is dysfunction of alpha motor neurons that stimulate mus-
cular fiber, and it also affects the gamma motor neurons 
distributed in the muscle spindles to reduce afferent feed-
back and weaken myotonus [4]. 
DURATION  OF  ACTION  AND 
FUNCTIONAL  RECOVERY
    Skeletal muscle strength generally weakens 2-5 days 
after BTX injection, minimizes within 2 weeks and then 
recovers. This weakening effect continues from 6 weeks to 
6 months (median 3-4 months), and the injection dose in-
fluences  the  degree  and  period  of  denervation.  Muscle 
atrophy and change in muscular fiber appear during the 
period when the effect is strong, and the effect gradually 
weakens after 2-3 months. Recovery from local paralysis 
i s  e x p l a i n e d  i n  t w o  w a y s :  n e u r o n a l  b u d d i n g  a n d  r e -
generation of SNARE complexes [3,4]. 
IMMUNOGENICITY  OF  BTX  AND 
DIFFERENCE  IN  SEROTYPE
    Clinically, BTX is used locally, but it is known to dis-
tribute in the blood through systemic absorption. Because 
of less potent BTX coming into the market and high-dose 
BTX being used often, the danger of antibody formation 
that neu tra lizes the eff ect of B TX has increased. When 
antibodies are formed, the effect and duration of BTX in-
jection decreases. In the case of BTX-A in dystonia, anti-
body formation rate is 1-5% in standard dosage [2].
    Since BTX-B proteins do not combine with the areas 
with which BTX-A proteins combine, BTX-A antibodies do 
not  interfere BTX-B  [5], and treatments using  different 
serotypes of BTX have been developed for patients with 
activated immune systems. However, BTX-B has a lower 
c h a i n  s e p a r a t i o n  r a t e ,  w h i c h  m e a n s  l o w e r  p o t e n c y  a n d 
higher dosages, leading to increased immunogenic poten-
tial through more exposure of proteins. Therefore, more 
clinical  research  in  this  area  is  needed.  Compared  to 
BTX-B, BOTOX
TM is 40-70 times and DYSPORT
TM is 10-20 
t i m e s  s t r o n g e r .  H o w e v e r ,  t h e r e  i s  n o  a c c u r a t e  d a t a  o n 
con v ersion f actors between BTX-B and BTX-A, so it is 
difficult to compare efficacy, side effects and cost. 
    In treating patients with dystonia, BTX-B showed 
higher frequency of dry mouth and visual impairment than 
BTX-A [6], and although this is an undesirable complica-
tion, it is an interesting phenomenon because it means 
that BTX-B has higher affinity to autonomic nerve fibers. 
USAGE,  SIDE  EFFECTS  AND 
PRECAUTIONS
    The method, dosage, and frequency of BTX injection 
should depend on patient circumstances. For deep muscles, 
it helps to conduct BTX injection under radiograph, elec-
tromyography and electrical stimulation. Dosage should be 
decided on the basis of symptom(s), muscle type, weight, 
previous injection reaction, and accompanying diseases. It 
is recommended to use the minimum amount needed to 
achieve the desired effect while minimizing adverse effects. WS Sim / Application of Botulinum Toxin in Pain Management 3
Fig. 1. Inhibition of acetylcholine and neurotransmitter 
release from motor neuron and nociceptor by botulinum 
toxin (BTX) may reduce pain.
Side effects such as pain in the injected area, bruises and 
muscular weakness are most common, while fatigue, fever, 
dry mouth, and ptosis can also appear 1-2 weeks after 
injection. Rarely, an allergic reaction can be triggered and 
i n j e c t i o n  i n  a r e a s  n e a r  t h e  n e c k  a n d  m o u t h  c a n  c a u s e 
dysphagia. Headache, lethargy, and muscle pain can ap-
pear when an excessive dosage is used, but all side effects 
are temporary and reversible [7].
    BTX should not be used when there is an infection in 
the injection site, allergy to the medication, myasthenia 
gravis, or Eaton Lambert syndrome. BTX injection is also 
prohibited in children less than 12 years of age and preg-
nant and nursing mothers. Caution is needed for patients 
with peripheral motor neuron disease, neuromuscular con-
duction disease, and those taking drugs that can interfere 
with neuromuscular conduction [7]. 
NEW  DOMAIN  OF  BTX:  PAIN
    BTX weakens muscles with acute pain and ceases the 
r e p e t i t i o n c y c l e  o f  m u s c l e  s p a s m  a n d  p a i n,  t o  m a in t a in 
pain  alleviation  and  allow  physical  activities  that  help 
long-term recovery. 
    The exact mode of action of BTX for pain relief has 
not been revealed completely, but it may be multifactorial 
(Fig. 1). Reduction of dystonia and muscle spasm is consid-
ered to be the effect of acetylcholine secretion, but in re-
cent animal testing, other analgesic effects of BTX have 
been suggested [8]. It has been suggested that BTX sup-
presses  the  secretion  of  neurotransmitters  directly  de-
creasing peripheral sensitization and indirectly decreasing 
central sensitization. However, there is still some debate 
[4,8]. 
POSSIBLE  MECHANISM  OF  PAIN  RELIEF
    The specificity of BTX on cholinergic nerves is due to 
specific acceptors in the nerve terminal membrane, but it 
has  been  revealed  experimentally  that  BTX  suppresses 
other  neurotransmitters  such  as  norepinephrine  in  the 
s a m e  m o d e  o f  a c t i o n  i t  d e s t r o y s  S N A R E  c o m p l e x e s  [ 2 ] . 
However, many nerve cells do not have specific acceptors 
for BTX; in addition, it is absorbed only through pinocytotic 
pathways and is therefore not highly effective. As a result, 
BTX is useful for neuromuscular diseases because of its 
high affinity to cholinergic synapses. 
    However, several ex ceptions to BTX’s acceptor specif-
icity have been noted. For example, BTX-A affects secre-
tion of substance P in nerves cultured from the dorsal root 
ganglion of mouse embryos and decreases the secretion 
of ca l citonin gen e-r e lated pe p ti d e (CG RP) in c u l tur es of 
neurons from the trigeminal ganglion. Furthermore, sub-
cutaneous  injection  of  BTX-A  showed  decreased  in-
flammation from stimulus, secretion of glutamate in the 
nociceptor’s axon, and activity of spinal dorsal horn neu-
rons in mice [2]. These results suggest that BTX-A directly 
suppresses nociceptors through suppressing the secretion 
of neurotransmitters that act on nerve conduction and pe-
r i p h e r a l  a n d  c e n t r a l  s e n s i t i z a t i o n s .  T h e r e f o r e ,  B T X  i s  a 
strong suppressant of acetylcholine as well as providing 
pain relief and anti-inflammatory effects by suppressing 
secretion of other neurotransmitters and neuropeptides [9]. 
    More research is needed to explain the suppressant 
effect of BTX on pain receptors, but BTX’s mode of action 
can be considered as follows: 1) normalization of muscular 
hyperactivity, 2) normalization of excessive muscle spindle 
activity, 3) retrograde neuronal flow to the CNS, 4) sup-
pression  of neuropeptide secretion in nociceptors in  the 
central and peripheral nervous systems [10]. 
CLINICAL  APPLICATION
    BTX is used in the treatment of strabismus, blephar-
ospasm, hemifacial spasm, adductor spasmodic dysphonia, 
bruxism,  mandibular  dystonia,  cervix  dystonia,  local  or 
segmental dystonia, hypercontractility of the internal anal 
sphincter, detrusor dyssynergy, spasticity, and stuttering 
[1,2]. As the safety of BTX has been shown, it is also used 
in beauty treatments, hyperhidrosis, sialorrhea and neuro-
pathic pain. The efficacy of BTX in these diseases can be 4 Korean J Pain Vol. 24, No. 1, 2011
explained by the effect on cholinergic nerve conduction. 
    BTX has been used for 20 years in the treatment of 
diseases with accelerated muscle contraction and tension. 
Ex p e ri m e n t a l  r es ea r c h o f B T X  in  n e w  d o m a i ns  i s b e in g 
conducted, especially in the treatment of primary head-
a che and cervica l, scapular and lum bar m y of ascial pain 
syndrome (MFPS) [1,2]. 
1. Myofascial pain syndrome
    As the effect of common treatment for MFPS is in 
many cases unsatisfactory, the treatment is needed for a 
long time. In addition, as painkillers are used long-term, 
this ineffective treatment is costly and complications such 
as gastrointestinal and renal toxicity can be a problem. On 
t h e  o t h e r  h a n d ,  s i m p l e  B T X  i n j e c t i o n s  a c c o m p a n i e d  b y 
p h y s i o t h e r a p y  c a n  b e  e f f e c t i v e  f o r  1 - 3  m o n t h s  w i t h o u t  
these complications. However, fatigue, muscle pain, and 
headaches  can  appear  as  complications  for  a  few  days 
[11-13]. 
    Göbel et al. [14] verified the usefulness and safety of 
BTX in MFPS through a comparative study that observed 
pain where BTX was injected in trigger points on the neck 
or shoulder. There have also been reports that BTX was 
effective for a patient with temporomandibular joint dys-
function [15] and a patient with fasciitis in the foot [16]. 
2. Chronic back pain
    F oster et al. [17] verified long-term effectiveness of 
BTX in patients with chronic back pain through a dou-
ble-blind randomized study. 60% of the BTX group injected 
with 40-50 units in 5 areas in the muscle next to the spine 
showed a significant decrease in pain, and the pain relief 
was maintained for 3-4 months. However, one study on 
BTX’s efficacy for chronic back pain was problematic be-
cause it was conducted on only a few patients with varying 
pathophysiology [18].
3. Headache
    Generally, BTX-A shows a consistent eff ectiveness f or 
migraines [19,20], and the treatment effect appears usu-
a ll y  3  m o n t h s a ft e r  i n j ec t i o n.  H y p o t o n i a ,  n ec k  s t iff n es s 
and  neck  pain  are  the  most  common  complications  at 
about 3% [20]. BTX-A has a preventative effect on mi-
graines and works well in the treatment of post-whiplash 
and cervicogenic headaches. However, there are also re-
ports that BTX-A does not have an effect on the degree 
of pain, number or duration of episodic migraines [21]. 
    The treatmen t mechanism of B TX f or migraines is un-
certain, but it has been suggested that it is due to muscle 
relaxation and resultant decrease in pressure on the trige-
minal nerve. The fact that many patients with migraines 
ha v e h ypertr op hic corrugator m uscles that pressure the 
trigeminal nerve and temporal region supports this theory 
[22]. Another suggested treatment mechanism is asso-
ciated  with  neurotransmitters  through  influence  on  the 
peripheral and central nervous systems. 
    There are reports that B TX is eff ectiv e on chronic dai-
ly headaches. For tension headaches, tension relaxation 
was anticipated due to the contraction of cephalic muscle. 
However, in many clinical tests, BTX was found to be in-
effective or less effective on tension headaches in compar-
ison with migraine. The ineffectiveness is believed to result 
from the weaker central sensitization compared to the case 
of migraines. 
    There is a report that BTX decreased the duration and 
degree  of  pain  and  increased  joint  motion  range  in 
post-whiplash headaches and muscle pain [23]. 
4. Arthralgia
    BTX-A is known to combine with nociceptors in the 
C fiber to suppress secretion of pain transmitters, such as 
substance P, CGRP, and glutamate, which leads to a de-
crease in pain transmission and peripheral sensitization. 
This result implies BTX can be used in the clinical treat-
ment of various arthralgias because BTX joint injection af-
f e c t s  e f f e r e n t  n e r v e  f u n c t i o n  ( s e c r e t i o n  o f  n e u r o -
transmitters in the sensory nerves) [24]. 
    There have been studies of patients with knee osteo-
arthritis or pain after knee artificial joint surgery that ob-
served improvement in pain and function. However, further 
research is necessary on possible complications such as 
a g g r a v a t i o n  o f  i n f e c t i o n  a n d  p a i n ,  e f f e c t  o n  m u s c l e  
strength and sensory nerves, and neuropathic joint degen-
eration [24]. 
5. Chronic pelvic pain
    In chronic genitourinary pain syndrome, BTX-A has 
been associated with a decrease in muscle tension and di-
rect pain relief [25]. There are also studies showing that 
pain and function improved in vulvodynia, vaginismus, le-
vator  ani  convulsion,  chronic  prostatitis,  and  interstitial 
cystitis when BTX was injected [25]. WS Sim / Application of Botulinum Toxin in Pain Management 5
6. Neuropathic pain
    Secretion of pro-inflammatory agents (cytokines, ad-
enosine, bradykinin, serotonin, prostaglandins) sensitizes 
neurotransmission and increases pain sensation by creat-
ing a temporary neuropathic state. The theory that BTX 
can treat neuropathic pain by suppressing the secretion of 
neurotransmitters to affect pain transmission, peripheral 
and central sensitization needs to be verified further [2]. 
    Patients with complex regional pain syndrome in the 
areas near the neck, below the larynx, or near the scapula 
usually accompany MFPS in the same area, and depending 
on m uscle size, 25-50 IU of BTX-A can be injected in 
trigger points. There are reports of improvement in pain 
and function after injecting BTX-A or -B for patients with 
neuropathy after spinal cord injury, neuralgia after herpes 
zoster, trigeminal neuralgia, and pain after amputation of 
upper or lower limbs [26]. 
CONCLUSION
    BTX can be safely used in the treatment of chronic 
p a i n  w h e r e  c o m p l i c a t i o n s  f r o m  d r u g  t r e a t m e n t  a r e  a  
c o n c e rn . T h e in i t i a l  c o s t  o f B T X  t r ea t m e n t  c a n  b e e x-
pensive, but it has the advantage that there are less com-
plications and hospitalization is unnecessary or of short 
duration. Furthermore, treatment effect can be maintained 
for  3-4  months,  while  supplementary  medications  are 
reduced. 
    Further research is necessary on the exact treatment 
mechanism of BTX for chronic pain and its role in multi-
factorial  treatment.  Future  research  should  include  ex-
panding the domain of treatable diseases, comparing in-
jection intervals, formation of antibodies, cost, and com-
plications such as muscle weakness. 
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